Cyclophosphamide- Antifungals Interactions in Patients Undergoing Hematopoietic Stem Cell Transplantation: What Should We Know About it?
Abstract
No Abstracs No Abstracs No Abstracs
1. De Jonge ME, Huitema AD, Rodenhuis S, et al. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet. 2005;44(11):1135-64.
2. Batchelor R, Thomas C, Gardiner B, et al., editors. When azoles cannot be used: the clinical effectiveness of intermittent liposomal amphotericin prophylaxis in hematology patients. Open Forum Infect Dis. 2021; 8(7):ofab113.
3. Popa MA, Wallace KJ, Brunello A, et al. Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy. J Geriatr Oncol. 2014;5(3):307-14.
4. Yule S, Walker D, Cole M, et al. The effect of fluconazole on cyclophosphamide metabolism in children. Drug Metab Dispos. 1999;27(3):417-21.
5. Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood. 2004;103(4):1557-9.
6. Upton A, McCune JS, Kirby KA, et al. Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2007;13(7):760-4.
7. Leather HL. Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know. Bone Marrow Transplant. 2004;33(2):137-52.
8. Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet. 2001;357(9270):1766-7.
9. Shibata Y, Tamemoto Y, Singh SP, et al. Plausible drug interaction between cyclophosphamide and voriconazole via inhibition of CYP2B6. Drug Metab Pharmacokinet. 2021:39:100396.
10. Poon A, Ly LK. Common potential drug interactions following hematopoietic cell transplantation. Thomas’ Hematopoietic Cell Transplantation. Stem Cell Transplantation.1st edn.Oxford, UK: Wiley-Blackwell, 2015.
11. Campen CJ, Vogel WH, Shah PJ. Managing drug interactions in cancer therapy: a guide for the advanced practitioner. J Adv Pract Oncol. 2017;8(6):609-620.
12. Gupta AK, Daigle D, Foley KA. Drug safety assessment of oral formulations of ketoconazole. Expert Opin Drug Saf. 2015;14(2):325-34
13. Duckwall MJ, Gales MA, Gales BJ. Inhaled amphotericin B as aspergillosis prophylaxis in hematologic disease: an update. Microbiol Insights. 2019:12:1178636119869937.
14. Mendoza-Palomar N, Soques E, Benitez-Carabante MI, et al. Low-dose liposomal amphotericin B for antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell transplantation. J Antimicrob Chemother. 2020;75(8):2264-2271.
15. Broto M, McCabe R, Galve R, et al. A high-specificity immunoassay for the therapeutic drug monitoring of cyclophosphamide. Analyst. 2019;144(17):5172-8.
2. Batchelor R, Thomas C, Gardiner B, et al., editors. When azoles cannot be used: the clinical effectiveness of intermittent liposomal amphotericin prophylaxis in hematology patients. Open Forum Infect Dis. 2021; 8(7):ofab113.
3. Popa MA, Wallace KJ, Brunello A, et al. Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy. J Geriatr Oncol. 2014;5(3):307-14.
4. Yule S, Walker D, Cole M, et al. The effect of fluconazole on cyclophosphamide metabolism in children. Drug Metab Dispos. 1999;27(3):417-21.
5. Marr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood. 2004;103(4):1557-9.
6. Upton A, McCune JS, Kirby KA, et al. Fluconazole coadministration concurrent with cyclophosphamide conditioning may reduce regimen-related toxicity postmyeloablative hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2007;13(7):760-4.
7. Leather HL. Drug interactions in the hematopoietic stem cell transplant (HSCT) recipient: what every transplanter needs to know. Bone Marrow Transplant. 2004;33(2):137-52.
8. Ahmad SR, Singer SJ, Leissa BG. Congestive heart failure associated with itraconazole. Lancet. 2001;357(9270):1766-7.
9. Shibata Y, Tamemoto Y, Singh SP, et al. Plausible drug interaction between cyclophosphamide and voriconazole via inhibition of CYP2B6. Drug Metab Pharmacokinet. 2021:39:100396.
10. Poon A, Ly LK. Common potential drug interactions following hematopoietic cell transplantation. Thomas’ Hematopoietic Cell Transplantation. Stem Cell Transplantation.1st edn.Oxford, UK: Wiley-Blackwell, 2015.
11. Campen CJ, Vogel WH, Shah PJ. Managing drug interactions in cancer therapy: a guide for the advanced practitioner. J Adv Pract Oncol. 2017;8(6):609-620.
12. Gupta AK, Daigle D, Foley KA. Drug safety assessment of oral formulations of ketoconazole. Expert Opin Drug Saf. 2015;14(2):325-34
13. Duckwall MJ, Gales MA, Gales BJ. Inhaled amphotericin B as aspergillosis prophylaxis in hematologic disease: an update. Microbiol Insights. 2019:12:1178636119869937.
14. Mendoza-Palomar N, Soques E, Benitez-Carabante MI, et al. Low-dose liposomal amphotericin B for antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell transplantation. J Antimicrob Chemother. 2020;75(8):2264-2271.
15. Broto M, McCabe R, Galve R, et al. A high-specificity immunoassay for the therapeutic drug monitoring of cyclophosphamide. Analyst. 2019;144(17):5172-8.
| Files | ||
| Issue | Vol 18 No 3 (2024) | |
| Section | Editorial | |
| DOI | https://doi.org/10.18502/ijhoscr.v18i3.16112 | |
| Keywords | ||
| Amphotericin B Azole Antifungal Bone Marrow Transplantation Chemotherapy Drug-Drug Interactions Echinocandins | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
How to Cite
1.
Zarrabi S, Vaezi M, Shahrami B. Cyclophosphamide- Antifungals Interactions in Patients Undergoing Hematopoietic Stem Cell Transplantation: What Should We Know About it?. Int J Hematol Oncol Stem Cell Res. 2024;18(3):306-310.
